Life Sciences FDA, Global Regulatory & Market Access

McDermott Will & Schulte· July 28, 2026

McDermott Will & Schulte maintains a specialized focus on FDA regulations, global regulatory compliance, and market access strategies within the life sciences sector. This expertise is particularly relevant for medical device companies that must navigate rigorous approval pathways and international standards to bring products to market. Ensuring compliance with these complex legal frameworks is essential for maintaining competitive advantage and operational stability in the global healthcare market.

Read the full story at McDermott Will & Schulte

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to McDermott Will & Schulte.

More in Medical Devices

AmorePacific Holdings Partners with Hire Corporation to Develop Integrated Skin Care Medical Device Solutions

AmorePacific Holdings has signed an investment contract with Hire Corporation, a specialist in skin care medical devices, to co-develop integrated aesthetic solutions. This partnership aims to bridge the gap between medical device technology and post-procedure skin care management, targeting the global beauty and medical markets. For the medical device sector, this move signifies a strategic convergence of traditional skin science with advanced aesthetic hardware to enhance patient outcomes and clinical distribution.

July 27, 2026

HIER Corporation Secures Strategic Investment from Amorepacific Holdings to Strengthen Beauty-Medical Collaboration

HIER Corporation, a specialist in aesthetic medical devices, has entered into a strategic investment agreement with Amorepacific Holdings to advance collaboration in the beauty-medical sector. The partnership aims to bridge the gap between professional clinical treatments and daily skincare through joint research and development of next-generation medical solutions. This move highlights a growing trend of convergence between traditional dermatological science and advanced medical device technology within the global aesthetics market.

July 27, 2026

CLINUVEL to Cut Workforce and Relocate to New York Amid Broader Biopharma Restructuring

CLINUVEL PHARMACEUTICALS has announced plans to reduce its global workforce by up to 20% and relocate its headquarters to New York to prioritize the U.S. market. This strategic shift coincides with significant headcount reductions across the sector, including major cuts at Novartis and potential staff departures at EMD Serono due to new office attendance policies. These developments highlight a broader industry trend of realigning operational expenditures and geographic footprints to better access capital and key commercial territories.

July 26, 2026

CDSCO Issues Final Medical Device Software Guidance to Strengthen MDSW Regulation

The Central Drugs Standard Control Organisation (CDSCO) has released a final guidance document for Medical Device Software (MDSW) to provide clearer regulatory expectations under the Medical Devices Rules, 2017. This framework addresses the rapid evolution of AI, cloud computing, and connected health technologies by establishing rigorous standards for quality, safety, and compliance. For the medical device sector, this move ensures that manufacturers, importers, and researchers have a structured path for documentation, quality management, and market approval in India.

July 23, 2026